AN2 THERAPEUTICS INC · Data as of 2026-09-08
Q3 2026
The Company recently held a pre-IND meeting with the FDA and now plans to expand the Phase 2 study (EBO-PV-201) to add sites in the U.S. and Australia, with an IND filing expected in the third quarter of 2026.Source filing
Q4 2026
Subject to regulatory clearance and enrollment progress, the Company expects to provide periodic data readouts beginning as early as the fourth quarter of 2026 and throughout 2027.Source filing
2027
The Company anticipates releasing Part 1 data periodically throughout 2027.Source filing
late 2027
The Company anticipates reporting topline results in late 2027, subject to enrollment progress.Source filing